1-2 of 2
Andrea Hochhaus, Prof. Dr.
Close
Sort by
Journal Articles

Bosutinib Vs Imatinib for Newly Diagnosed Chronic Myeloid Leukemia (CML) in the BFORE Trial: 18 Month Follow-up

Carlo Gambacorti-Passerini, MD, Michael W. Deininger, MD PhD, Michael J. Mauro, MD, Charles Chuah, MD, Dong-Wook Kim, MD PhD, Iryna Dyagil, MDPhD, Natalia Glushko, Dragana Milojkovic, MBBS, PhD, Philipp D. le Coutre, MD, Valentín García Gutiérrez, PhD, Rocco J. Crescenzo, DO, FACOI, Eric Leip, PhD, Nathalie Bardy-Bouxin, PhD, Andrea Hochhaus, Prof. Dr., Timothy H. Brümmendorf, Jorge E. Cortes, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 896.
https://doi.org/10.1182/blood.V130.Suppl_1.896.896
Published: 2017
Journal Articles

Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: 12-Month Patient-Reported Outcomes from the BFORE Trial

Jorge E. Cortes, MD, Carlo Gambacorti-Passerini, MD, Michael W. Deininger, MD PhD, Michael J. Mauro, MD, Charles Chuah, MD, Dong-Wook Kim, MD PhD, Iryna Dyagil, MDPhD, Nataliia Glushko, Dragana Milojkovic, MBBS, PhD, Philipp D. le Coutre, MD, Valentín García Gutiérrez, PhD, Laurence Reilly, Allison Jeynes-Ellis, Rocco J. Crescenzo, DO, FACOI, Carla Mamolo, Arlene Reisman, Nathalie Bardy-Bouxin, PhD, Andrea Hochhaus, Prof. Dr., Timothy H. Brümmendorf
Journal: Blood
Blood (2017) 130 (Supplement 1): 2895.
https://doi.org/10.1182/blood.V130.Suppl_1.2895.2895
Published: 2017